While red blood cell (RBC) transfusion represents one of the most common interventions in hospitalized patients, transfusion is not without risk. Allogeneic RBC exposure can result in the development of RBC alloantibodies, which can delay subsequent transfusions and lead to life-threatening complications. Recent data generated using animal models, sophisticated human immunology and epidemiological studies have resulted in an unprecedented growth in the field of RBC alloimmunization. This session will integrate findings obtained in a variety of animal models, human immunology and a growing number of epidemiological studies that have all been designed to understand factors that regulate RBC alloimmunization. In doing so, this session will assimilate these different fields to provide a greater understanding of the factors that may predict and ultimately prevent RBC alloimmunization in at risk patients.
Define distinct differences in RBC alloimmunization immune pathways as defined by recent animal models of alloimmunization.
Discuss the unique immune responses that correlate with alloantibody responder status in chronically transfused patients with sickle cell disease.
Identify key epidemiological associations in transfused recipients that correlate with the likelihood of developing alloantibodies following RBC transfusion.
Please note:Karina Yazdanbakhsh, PhD and Jaap Jan Zwaginga did not consent to be recorded; therefore, the on-demand presentation and handout have been modified accordingly.
Emory University School of Medicine
Executive Director of Research,
Lindsley F. Kimball Research Institute, New York Blood Center